About: Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.99 (-3.40%)
ZNTL NASDAQ Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals Llc share price
Atividade de preço de ZNTL
Último preço
$ 1,990
Variação (24h)
-0,07 USD (3,40%)
Volume
1.44M
Volume (média 4 sem.)
-
Abertura
$ 2,06
Variação do dia
$ 1,97 - $ 2,11
Fechamento anterior
$ 2,06
Último negócio
29 Oct, 8:19 pm GMT+0
Atrasado
29 Oct, 8:19 pm GMT+0
ZNTL price performance
Atrasado
29 Oct, 8:19 pm GMT+0
quote.marketSignals